Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
Tagawa S, Nanus D, Posadas E, Petrylak D, Bruce J, Lim E, Peng W, Maul R, Gonzalez M, Tran N. Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2014, 32: 205-205. DOI: 10.1200/jco.2014.32.4_suppl.205.Peer-Reviewed Original ResearchDose-limiting toxicityMetastatic castration-resistant prostate cancerAbiraterone acetateExperienced dose-limiting toxicityProstate-specific antigen (PSA) declineCastration-resistant prostate cancerPhase Ib studyMaximum plasma concentrationConcentration-time curveIntolerable toxicityPSA progressionMedian timeSystemic exposurePlasma concentrationsProstate cancerIb studyPharmacokinetic parametersFurther evaluationWk 2Wk 7CohortToxicityComplementary mechanismsProportion of PtSafety